Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Neoplasms by Site 1Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Bronchial Neoplasms 1

Interventions

Pemetrexed 7Carboplatin 7Cisplatin 5pembrolizumab 4durvalumab 4osimertinib 3Paclitaxel 3selpercatinib 2pralsetinib 2cobimetinib 2Radiosurgery 2Erlotinib Hydrochloride 2130-nm albumin-bound paclitaxel 2trametinib 1taletrectinib 1sotorasib 1repotrectinib 1patritumab 1napabucasin 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1exemestane 1enzalutamide 1entinostat 1dabrafenib 1ceralasertib 1cemiplimab 1camrelizumab 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × napabucasin × Thoracic × Clear all
NCT02826161 2023-11-15

CanStem43L

Sumitomo Pharma America, Inc.

Phase 3 Terminated
4 enrolled 6 charts
Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡